查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985797

酒精使用障礙市場：2026-2032年全球市場預測（依藥物類別、治療方法、劑型、最終用戶和分銷管道分類）

Alcohol Use Disorder Market by Drug Class, Treatment Type, Formulation, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，酒精使用障礙市場價值將達到 13.7 億美元，到 2026 年將成長到 14.6 億美元，到 2032 年將達到 21.7 億美元，複合年成長率為 6.78%。

主要市場統計數據
基準年 2025 13.7億美元
預計年份：2026年 14.6億美元
預測年份：2032年 21.7億美元
複合年成長率 (%) 6.78%

透過綜合護理路徑、長效藥物療法和數位化訪問模式，我們掌握酒精使用障礙治療領域不斷變化的格局，並為策略決策做出貢獻。

為了因應日益成長的實證治療需求，酒精使用障礙（AUD）的治療模式正在迅速變化，臨床實踐、藥物治療方案和治療模式都在融合融合。長效製劑和多方面治療方法的進步重新定義了治療討論的框架，而數位平台和遠端醫療則拓展了治療管道。因此，AUD的持續管理如今強調在不同的醫療環境中實現持續復健、個人化的治療方法組合以及長期參與策略。

應對酒精使用治療方法、數位存取管道、支付方獎勵和減少污名化等方面的多方面變化，因為酒精使用障礙的護理服務正在重組。

一系列變革正在重新定義整個醫療保健系統中酒精使用障礙（AUD）的識別、治療和管理方式。首先，治療方法創新已超越傳統的口服藥物，擴展到長效注射藥物，這些藥物能夠提高患者的用藥依從性並降低復發風險，迫使臨床醫生重新思考治療的起始和維持策略。隨著治療方法的多樣化，結合行為療法和藥物療法的綜合治療方法再次變得至關重要，這些方法旨在增強短期治療效果並改善長期康復軌跡。

本研究分析了 2025 年關稅變化將如何影響酒精使用障礙治療供應鏈的在地化、籌資策略的調整以及製造業的韌性。

2025年美國關稅調整給藥品採購、供應鏈成本和製造商籌資策略帶來了新的變化，並對酒精使用障礙相關產品和分銷管道產生了累積影響。關稅帶來的成本壓力迫使製造商重新評估其製造地和供應商契約，促使其轉向本地化採購和替代原料供應商。這些調整影響了口服片劑、發泡製劑和注射劑的前置作業時間和庫存管理，導致製造商更加依賴緩衝庫存和多元化的物流合作夥伴。

我們從藥物類別、治療方法、醫療保健環境、分銷管道和製劑策略等方面提取關鍵細分見解，以指導商業化和臨床實施。

精細的市場細分分析揭示了每種藥物類別、治療方法、醫療機構、分銷管道和劑型所面臨的明確機會和實施要求。依藥物類別分類，市場包括Acamprosate、Disulfiram和納曲酮。Acamprosate發泡和口服錠分別針對不同的依從性和耐受性需求。Disulfiram主要以口服片劑形式使用，強調用藥監督和行為療法架構。納曲酮有注射劑和口服藥片兩種劑型，使臨床醫生能夠根據患者的依從性風險和合併症情況，制定個人化的治療啟動策略。這些差異指南臨床定位和通訊，重點是突顯療效、依從機制和相對耐受性。

區域比較趨勢揭示了美洲、歐洲、中東、非洲和亞太地區支付方的複雜性、監管異質性以及利用數位技術的准入管道。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的治療可近性、監管方式和服務提供模式產生了重大影響。在美洲，整合的醫療保健系統和不斷擴展的遠端醫療基礎設施正在推動聯合治療模式和長效注射藥物的快速普及。然而，不同的支付方環境要求靈活的報銷策略和令人信服的衛生經濟學論證，以確保新治療方法被納入處方藥清單和醫保覆蓋範圍。此外，該地區的跨境供應鏈正在動態應對關稅和物流的變化，從而促進區域採購的調整。

為了促進採用和維持存取權限，我們考慮採用一種結合多元化產品組合、通路夥伴關係、真實世界數據 (REW) 產生和供應鏈彈性的企業策略。

企業層面的關鍵趨勢集中在產品組合多元化、通路夥伴關係以及對患者支援基礎設施的投資。主要企業和專業經銷商越來越重視整合式商業模式，將產品供應與用藥依從性計畫、數位化監控工具和醫療專業人員培訓相結合，以加速產品推廣並最佳化治療效果。製藥公司與專業藥房和遠端醫療服務提供者之間的策略夥伴關係，簡化了長效療法的啟動流程，並支持患者從住院過渡到門診治療期間的持續護理。

我們優先考慮供應鏈韌性、綜合藥物治療和行為治療方案以及數位化醫療，同時協調與支付方的合作關係，以確保永續的醫療服務改善。

產業領導企業應採取雙管齊下的策略，將戰術性的業務永續營運與長期的臨床和商業性定位相結合。短期內，企業必須優先考慮供應鏈多元化，並實施雙源採購和區域生產安排，以減輕關稅波動的影響，確保口服、發泡和注射藥物的穩定供應。同時，他們應與醫院藥房、專科藥房和零售合作夥伴協調採購和庫存策略，以確保在急診和維持治療環境中藥物的供應。

我們採用了一種混合方法來整合證據，透過與關鍵相關人員的訪談、臨床文獻、監管訊號和情境建模進行三角驗證，以確保嚴格、實際的應用。

本研究途徑採用混合研究方法，結合了定性研究和對同行評審文獻、臨床指南、監管資訊以及公開政策聲明的整合分析。主要研究內容包括對住院和門診臨床醫生、醫院和專科藥房的採購經理以及生產商和經銷商的高管進行結構化訪談。透過這些研究，我們從第一線觀點深入了解了藥物推廣的促進因素、管理障礙以及劑型和分銷管道選擇對營運的影響。

我們將治療方法創新、交付方式和營運韌性的相互作用整合起來，以確定永續的臨床和商業性影響的優先事項。

治療方法、交付管道和政策的融合趨勢，正為酒精使用障礙治療領域的相關人員創造一個關鍵的轉折點。配方創新和綜合治療方法正在拓展臨床醫生可用的工具箱，而數位化平台和不斷演變的報銷模式則為持續參與和價值體現開闢了新的途徑。供應鏈和價格壓力凸顯了營運韌性的重要性，但同時也推動了對區域產能和多元化採購的策略投資，從而確保長期穩定性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：酒精使用疾患市場：依藥物類別分類

  • Acamprosate
    • 發泡
    • 口服錠劑
  • Disulfiram
  • 納曲酮
    • 注射藥物
    • 口服錠劑

第9章：酒精使用疾患市場：依治療方法

  • 行為療法
    • 認知行為療法
    • 家庭治療
    • 動機強化療法
  • 聯合治療
    • 認知行為療法合併藥物治療
    • 藥物治療
  • 藥物治療
    • 注射藥物
    • 口服藥物

第10章：酒精使用疾患市場：以劑型分類

  • 分散片
  • 發泡
  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服錠劑
    • 立即發布
    • 緩釋

第11章：酒精使用障礙市場：以最終用戶分類

  • 家庭醫療保健
    • 家庭到府醫療服務
    • 遠端醫療
  • 醫院
    • 私立醫院
    • 公立醫院
  • 復健中心
    • 住院治療
    • 門診
  • 專科診所
    • 酒精康復診所
    • 精神病診所

第12章：酒精使用障礙市場：依通路分類

  • 醫院藥房
    • 私立醫院的藥房
    • 公立醫院藥房
  • 網路藥房
    • 電子商務網站
    • 行動應用
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房
  • 專科藥房
    • 專門治療酒精使用疾患的藥房
    • 普通專科藥房

第13章：酒精使用障礙市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：酒精使用障礙市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：酒精使用障礙市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國酒精使用疾患市場

第17章：中國的酒精使用疾患市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alkermes plc
  • Aurobindo Pharma Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • H. Lundbeck A/S
  • Lupin Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-351BAD503A27

The Alcohol Use Disorder Market was valued at USD 1.37 billion in 2025 and is projected to grow to USD 1.46 billion in 2026, with a CAGR of 6.78%, reaching USD 2.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.37 billion
Estimated Year [2026] USD 1.46 billion
Forecast Year [2032] USD 2.17 billion
CAGR (%) 6.78%

Framing the evolving Alcohol Use Disorder treatment landscape with integrated care pathways, long-acting pharmacotherapies, and digital access models to inform strategic decisions

The landscape of Alcohol Use Disorder (AUD) care is rapidly evolving as clinical practice, pharmacologic options, and delivery models converge to better meet the growing demand for evidence-based treatment. Advances in long-acting formulations and multimodal approaches have reframed treatment conversations, while digital platforms and telehealth have expanded pathways to care. Consequently, the continuum of AUD management now emphasizes sustained recovery, individualized therapeutic combinations, and durable engagement strategies across diverse care settings.

Clinicians and health system leaders are increasingly prioritizing integrated care pathways that combine behavioral interventions with pharmacotherapy, and payers are recalibrating coverage criteria in response to outcomes data and cost-of-care considerations. Meanwhile, regulatory movements and public health campaigns are shaping perceptions and access, underscoring the importance of adaptable clinical protocols and supply-chain resilience. This introduction outlines the main forces reshaping treatment paradigms, highlights the intersection of technology and therapeutics, and situates stakeholders to capitalize on actionable insights emerging across clinical, regulatory, and commercial domains.

Navigating multipronged changes in therapy modalities, digital access pathways, payer incentives, and stigma reduction that are reshaping Alcohol Use Disorder care delivery

A series of transformative shifts is redefining how AUD is identified, treated, and managed across healthcare systems. First, therapeutic innovation has expanded beyond traditional oral dosing to include injectable long-acting agents that improve adherence and reduce relapse risk, prompting clinicians to reconsider initiation and maintenance strategies. This therapeutic diversification is accompanied by renewed emphasis on combination approaches that align behavioral therapies with pharmacotherapies to bolster both short-term engagement and long-term recovery trajectories.

Concurrently, digital health solutions are changing patient touchpoints. Telehealth and remote monitoring enable continuity of care for patients in rural or underserved areas and facilitate stepped-care models that move patients between intensity levels according to real-time clinical signals. These digital pathways also create opportunities for novel adherence interventions and remote behavioral coaching that complement in-person services. Meanwhile, payer and regulatory environments are responding to these innovations with more nuanced coverage determinations and value-based contracting pilots that prioritize measurable outcomes over service volume.

Finally, public and provider awareness campaigns have shifted stigma-related barriers to care, increasing screening rates and early intervention. Collectively, these changes generate a more patient-centric, outcomes-oriented ecosystem that rewards integrated care, device-enabled adherence, and evidence-based combinations of behavioral and pharmacologic modalities. Stakeholders who align product development, distribution, and clinical training with these shifts are positioned to lead in both clinical impact and commercial performance.

Analyzing how 2025 tariff shifts catalyzed supply chain regionalization, procurement adaptations, and manufacturing resilience for Alcohol Use Disorder therapies

United States tariff adjustments in 2025 introduced new dynamics into pharmaceutical procurement, supply chain costs, and manufacturer sourcing strategies, with cumulative consequences for AUD-related products and distribution channels. Tariff-related cost pressures compelled manufacturers to reassess manufacturing footprints and supplier contracts, prompting shifts toward regionalized sourcing and alternative raw material suppliers. These adjustments influenced lead times and inventory practices for oral tablets, effervescent formulations, and injectable therapeutics, encouraging greater reliance on buffer inventories and diversified logistics partners.

In turn, hospital pharmacies, specialty pharmacies, and retail distributors adjusted procurement cadence to mitigate exposure to pricing volatility. Some providers increased contract durations with preferred suppliers to lock in price stability, while others explored consignment and group-purchasing arrangements to preserve access without disproportionately transferring costs to patients. These procurement adaptations affected the availability of both immediate-release and sustained-release oral formulations as well as injectable intramuscular and subcutaneous options, with downstream implications for initiation protocols and adherence programs.

Additionally, the tariff environment accelerated conversations around domestic manufacturing incentives and reshored capacity for critical excipients and finished-dose forms. Policymakers and industry leaders engaged in dialogue about incentives to stabilize supply chains and reduce systemic vulnerability. As a result, strategic planning for commercialization now routinely incorporates tariff scenario modeling, dual-sourcing strategies, and cost-pass-through considerations to maintain therapeutic continuity for patients while preserving financial viability for manufacturers and distributors.

Distilling operationally relevant segmentation insights across drug classes, treatment modalities, care settings, distribution channels, and formulation strategies to guide commercialization and clinical adoption

A nuanced segmentation analysis reveals distinct opportunities and execution imperatives across drug classes, treatment modalities, care settings, distribution channels, and formulation types. Within drug classes, the market includes acamprosate, disulfiram, and naltrexone; acamprosate's effervescent and oral tablet presentations support different adherence and tolerability profiles, disulfiram is primarily deployed in oral tablet form where supervised administration and behavioral frameworks are emphasized, and naltrexone is available both as injectables and oral tablets, enabling clinicians to tailor initiation strategies based on patient adherence risk and comorbidity profiles. These distinctions inform clinical positioning and messaging that emphasize onset of effect, adherence mechanisms, and comparative tolerability.

When examining treatment types, behavioral therapy, combined therapy, and pharmacotherapy create complementary pathways for intervention. Behavioral therapy encompasses cognitive behavioral therapy, family therapy, and motivational enhancement therapy, each addressing different psychosocial drivers of substance use and recovery readiness. Combined therapy-such as cognitive behavioral therapy with pharmacotherapy or motivational enhancement therapy with pharmacotherapy-integrates pharmacologic support with structured psychosocial interventions to enhance engagement and outcomes. Pharmacotherapy itself bifurcates into injectable and oral drugs, which present divergent needs in terms of dispensing, monitoring, and reimbursement practices. Understanding the interplay between these treatment paradigms is critical for designing integrated care protocols and training programs for multidisciplinary teams.

End-user segmentation further differentiates operational requirements and access patterns. Home healthcare, hospitals, rehabilitation centers, and specialty clinics each demand tailored service models. Home healthcare services leverage home visits and telehealth to extend continuity for patients who prefer community-based care, hospitals-both private and public-serve as high-acuity initiation points where inpatient stabilization and transitioning to outpatient care are coordinated, rehabilitation centers operate across inpatient and outpatient modalities to support structured recovery programs, and specialty clinics, including alcohol rehabilitation and psychiatric clinics, focus on longitudinal follow-up and complex case management. These distinctions affect referral pathways, reimbursement mechanisms, staffing models, and the design of adherence support services.

Distribution channel segmentation highlights the importance of channel-specific strategies. Hospital pharmacies-split between private and public institutions-must balance formulary access and acute-care needs, online pharmacies accessed via e-commerce websites and mobile apps facilitate convenience and discreet delivery for maintenance therapy, retail pharmacies comprised of chain and independent outlets provide widespread dispensing capability and patient counseling touchpoints, and specialty pharmacies, both addiction-focused and general, offer medication therapy management and care coordination for complex cases. Tailoring supply chain logistics, patient education, and specialty services to these channels enhances access and retention.

Finally, formulation segmentation-dispersible tablet, effervescent tablet, injectable, and oral tablet-demands careful commercialization choices. Injectable forms include intramuscular, intravenous, and subcutaneous routes that vary in administration setting and clinical workflow, while oral tablets encompass immediate-release and sustained-release profiles that influence dosing frequency and adherence support needs. Bringing these formulation insights together enables manufacturers, payers, and providers to align product development, reimbursement strategies, and patient support programs with real-world clinical utilization patterns and operational constraints.

Comparative regional dynamics revealing payer complexity, regulatory heterogeneity, and digital-enabled access trajectories across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence treatment access, regulatory approaches, and service delivery models across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and expanding telehealth infrastructure have supported rapid adoption of combined therapy models and long-acting injectables, while diverse payer landscapes necessitate flexible reimbursement strategies and robust health economics narratives to secure formulary placement and coverage for newer modalities. Cross-border supply chains in the region also respond dynamically to tariff and logistics changes, prompting localized procurement adjustments.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and variable health system capacities create both challenges and targeted opportunities. High-income markets within this region often lead with structured national treatment guidelines and strong specialty clinic networks, supporting adoption of evidence-backed combination treatments and specialty pharmacy services. Conversely, lower-resource settings emphasize task-shifting, community-based interventions, and scalable behavioral programs, which present opportunities to leverage telehealth and simplified pharmacotherapy regimens that are easy to deploy at scale.

The Asia-Pacific region exhibits a mix of rapid urbanization, growing healthcare infrastructure investment, and distinct cultural attitudes toward substance use that shape demand and care pathways. Increasing investments in specialty clinics, expanding private hospital networks, and mobile health penetration create fertile ground for novel distribution channels such as mobile app-enabled pharmacy services and hybrid home healthcare models. Across regions, supply-chain resilience, regulatory alignment, and culturally tailored patient engagement approaches emerge as cross-cutting enablers for successful deployment of AUD therapeutics and integrated care services.

Examining company strategies that combine diversified portfolios, channel partnerships, real-world evidence generation, and supply-chain resilience to drive uptake and sustain access

Key company-level dynamics center on portfolio diversification, channel partnerships, and investments in patient support infrastructure. Leading manufacturers and specialty distributors increasingly prioritize integrated commercial models that pair product availability with adherence programs, digital monitoring tools, and clinician education to accelerate uptake and optimize outcomes. Strategic partnerships between pharmaceutical firms and specialty pharmacies or telehealth providers enable streamlined initiation processes for long-acting therapies and support continuity of care across inpatient and outpatient transitions.

Additionally, contract strategies and value-based arrangements are gaining prominence as payers seek measurable outcome improvements and cost containment. Companies that can demonstrate robust real-world evidence and offer bundled services-such as medication management, tele-coaching, and outcome tracking-are better positioned to negotiate favorable coverage terms. Supply-chain investments, including dual-sourcing, regional manufacturing partnerships, and contingency inventories, have become integral to preserving product availability and mitigating tariff-related disruptions.

Finally, companies that invest in clinician training, stigma-reduction campaigns, and culturally sensitive patient materials tend to secure stronger prescriber relationships and higher initiation rates. By aligning commercial efforts with evidence-based clinical practices and responsive distribution strategies, market participants can drive both clinical impact and sustainable business performance in a complex and rapidly evolving therapeutic area.

Prioritize supply-chain resilience, integrated pharmacotherapy and behavioral programs, and digital-enabled care while aligning payer partnerships for durable access gains

Industry leaders should adopt a dual-focus strategy that combines tactical operational resilience with long-term clinical and commercial positioning. In the near term, firms must prioritize supply-chain diversification, implementing dual-sourcing and regional manufacturing arrangements to reduce exposure to tariff-driven disruptions and ensure consistent access to oral, effervescent, and injectable formulations. At the same time, aligning procurement and inventory strategies with hospital pharmacies, specialty pharmacies, and retail partners will safeguard availability across both acute and maintenance settings.

Concurrently, organizations should invest in integrated care enablement by scaling programs that combine pharmacotherapy with evidence-based behavioral therapies. Embedding cognitive behavioral therapy, family therapy, and motivational enhancement therapy into care pathways alongside pharmacologic options encourages adherence and supports sustained recovery. Companies can accelerate adoption by funding clinician education, supporting multidisciplinary care teams, and offering reimbursement-ready value propositions grounded in real-world outcomes.

To capture long-term value, leaders must also prioritize digital engagement and home-based care models. Telehealth, mobile adherence tools, and remote monitoring expand reach and reduce barriers to care, especially when paired with specialty pharmacy support and telepharmacy services. Finally, fostering payer partnerships through transparent outcomes measurement and pilot value-based agreements will facilitate broader access; by demonstrating measurable improvements in clinical and economic endpoints, organizations can de-risk coverage decisions and create a favorable environment for innovative therapies and service bundles.

Employing a mixed-methods evidence synthesis that triangulates primary stakeholder interviews, clinical literature, regulatory signals, and scenario modeling to ensure actionable rigor

The research approach combined a mixed-methods design that integrated primary qualitative engagement with secondary synthesis of peer-reviewed literature, clinical guidelines, regulatory communications, and publicly available policy statements. Primary inputs included structured interviews with clinicians across inpatient and outpatient settings, procurement leaders at hospital and specialty pharmacies, and executives from manufacturers and distributors. These engagements provided frontline perspectives on adoption drivers, administrative barriers, and the operational implications of formulation and channel choices.

Secondary analysis synthesized clinical trial literature, guideline updates, and health system policy changes to contextualize primary insights and validate observed trends. The methodology emphasized triangulation: qualitative findings were cross-referenced with published clinical evidence and regulatory developments to strengthen analytic rigor. Scenario analysis simulated the operational impacts of supply-chain disruptions and tariff shifts, while thematic coding of interview transcripts identified recurring barriers and enablers related to initiation, adherence, and reimbursement.

Throughout, emphasis was placed on transparency and reproducibility. Data sources were documented, stakeholder selection criteria were specified to ensure representativeness across care settings and regions, and analytic steps were recorded to permit replication. This methodology supports defensible conclusions and actionable recommendations while reflecting the multifaceted realities of clinical practice, procurement, and commercialization in AUD care.

Synthesize the interplay between therapeutic innovation, delivery evolution, and operational resilience to define priorities for sustainable clinical and commercial impact

The converging trends in therapeutics, delivery channels, and policy create a decisive moment for stakeholders involved in Alcohol Use Disorder care. Innovations in formulation and integrated treatment approaches are expanding the toolkit available to clinicians, while digital platforms and evolving reimbursement paradigms create new pathways to sustain engagement and demonstrate value. Supply-chain and tariff pressures underscore the importance of operational resilience, yet they also incentivize strategic investments in regional capacity and diversified sourcing that can yield long-term stability.

In summary, success will hinge on coordinated action across product development, distribution, clinical training, and payer engagement. Stakeholders who proactively design integrated care models, invest in adherence-enabling technologies, and cultivate payer relationships anchored in real-world outcomes will be best positioned to improve patient trajectories and secure sustainable commercial performance. The pathway forward requires balanced attention to immediate operational risks and long-term clinical and economic value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alcohol Use Disorder Market, by Drug Class

  • 8.1. Acamprosate
    • 8.1.1. Effervescent Tablet
    • 8.1.2. Oral Tablet
  • 8.2. Disulfiram
  • 8.3. Naltrexone
    • 8.3.1. Injectable
    • 8.3.2. Oral Tablet

9. Alcohol Use Disorder Market, by Treatment Type

  • 9.1. Behavioral Therapy
    • 9.1.1. Cognitive Behavioral Therapy
    • 9.1.2. Family Therapy
    • 9.1.3. Motivational Enhancement Therapy
  • 9.2. Combined Therapy
    • 9.2.1. Cbt With Pharmacotherapy
    • 9.2.2. Met With Pharmacotherapy
  • 9.3. Pharmacotherapy
    • 9.3.1. Injectable Drugs
    • 9.3.2. Oral Drugs

10. Alcohol Use Disorder Market, by Formulation

  • 10.1. Dispersible Tablet
  • 10.2. Effervescent Tablet
  • 10.3. Injectable
    • 10.3.1. Intramuscular
    • 10.3.2. Intravenous
    • 10.3.3. Subcutaneous
  • 10.4. Oral Tablet
    • 10.4.1. Immediate Release
    • 10.4.2. Sustained Release

11. Alcohol Use Disorder Market, by End User

  • 11.1. Home Healthcare
    • 11.1.1. Home Visits
    • 11.1.2. Telehealth
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Rehabilitation Centers
    • 11.3.1. Inpatient
    • 11.3.2. Outpatient
  • 11.4. Specialty Clinics
    • 11.4.1. Alcohol Rehabilitation Clinics
    • 11.4.2. Psychiatric Clinics

12. Alcohol Use Disorder Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
    • 12.1.1. Private Hospital Pharmacies
    • 12.1.2. Public Hospital Pharmacies
  • 12.2. Online Pharmacies
    • 12.2.1. E-Commerce Websites
    • 12.2.2. Mobile Apps
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies
  • 12.4. Specialty Pharmacies
    • 12.4.1. Aud Specialty Pharmacies
    • 12.4.2. General Specialty Pharmacies

13. Alcohol Use Disorder Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Alcohol Use Disorder Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Alcohol Use Disorder Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Alcohol Use Disorder Market

17. China Alcohol Use Disorder Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alkermes plc
  • 18.6. Aurobindo Pharma Ltd.
  • 18.7. Cipla Limited
  • 18.8. Dr. Reddy's Laboratories Ltd.
  • 18.9. H. Lundbeck A/S
  • 18.10. Lupin Limited
  • 18.11. Sandoz International GmbH
  • 18.12. Sun Pharmaceutical Industries Ltd.
  • 18.13. Teva Pharmaceutical Industries Ltd.
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALCOHOL USE DISORDER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALCOHOL USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD